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COPD = chronic obstructive pulmonary disease; CT = computed tomography; PPM = potentially pathogenic micro-organism; VAT = ventilator-
associated tracheobronchitis.
Available online http://ccforum.com/content/9/3/255
Abstract
It is difficult to define ventilator-associated tracheobronchitis (VAT).
The most accepted definition includes fever (temperature >38°C),
new or increased sputum production, a microbiologically positive
respiratory sample with counts above the accepted thresholds and
absence of pulmonary infiltrates on chest X-ray. Although we have
no doubt that this pathologic process exists, the main controversy
lies on whether this entity has any impact on the outcome and,
thus, a specific therapeutic approach is suitable. We will discuss
the strengths and drawbacks of the article on this topic published
in this issue by Nseir et al.
Ventilator-associated tracheobronchitis (VAT) is a difficult
entity to define. Indeed, the recently published American
Thoracic Society/Infectious Diseases Society of America
guidelines [1] do not address this issue. VAT is defined as
the presence of fever (temperature >38°C), new or increased
sputum production, a microbiologically positive respiratory
sample (with counts above accepted thresholds), and
absence of pulmonary infiltrates on chest radiography. The
apparent crude incidence of VAT ranges from 3% to 10%
[2], but it is very difficult to determine the exact incidence and
importance of VAT for several reasons. First, the definition of
VAT has not been validated. There are no studies with
acceptable ‘gold standard’ techniques evaluating the
accuracy of the criteria mentioned above or other such
criteria. Second, the term ‘new or increased sputum
production’ is rather imprecise and depends on subjective
impression. Finally, to confirm the absence of infiltrates on a
chest radiograph, a computed tomography (CT) scan is
required. In fact, it is not possible with portable chest X-ray
machines to view some small infiltrates or opacities that may
be detected by CT scans.
However, we have no doubt that this entity exists from the
clinical point of view. This belief results from the findings of
post-mortem studies [3], in which it is not infrequent to find
high bacterial counts in lung samples without histological
pneumonia. In addition, some years ago Rouby and
coworkers [4] described the existence of bronchiolitis without
histological pneumonia in lung samples taken from
mechanically ventilated patients shortly after death.
Establishing comparisons with severe community-acquired
infections you can also observe patients with pneumonia and
patients with infectious bronchitis without pulmonary
infiltrates on chest radiography as is the case of chronic
obstructive pulmonary disease (COPD) or bronchiectasis.
The reason why some patients develop VAT and not
ventilator-associated pneumonia is unknown but is probably
due to a counterbalance in the local inflammatory response.
This hypothesis requires confirmation in prospective studies.
In the study presented in this issue of Critical Care, Nseir and
colleagues [5] report the results of a retrospective case–
control study conducted in patients with VAT. They were able
to include and match 55 patients. The criteria defining VAT
were those mentioned above. Those investigators excluded
patients with chronic respiratory failure, those with
tracheostomy, trauma patients and immunosuppressed
patients. Importantly, the matching criteria were very strict,
employing six different matching variables. However, cases
more frequently received prior antibiotic treatment than did
controls (72% versus 27%). Although the mortality rates
were similar in the two populations and the rate in patients
with VAT was not related to the adequacy of antibiotic
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treatment, the duration of mechanical ventilation and the
length of intensive care unit stay were almost double in cases
compared with controls. In a logistic regression analysis, VAT
was found to be independently associated with increased
duration of mechanical ventilation (odds ratio 3.5).
Importantly, all micro-organisms isolated in VAT patients were
potentially pathogenic micro-organisms (PPMs), and
Pseudomonas aeruginosa accounted for one-third of these
isolates.
The main reservations we have regarding this study and its
results are inherent to the definition of VAT and whether it
really exists, and are addressed above. However, in the
critical care arena we do see patients like those described by
Nseir and colleagues [5], although not very often.
The main issue raised by this study is the potential influence
of VAT on length of stay and duration of mechanically
ventilation. In relation to this, the first question that clinicians
would ask is whether VAT must be treated with antibiotics
and for how long. Although that study cannot specifically
address this issue, there is indirect evidence that support
administration of antibiotics to patients with VAT. In a study
conducted by Nouira and colleagues [6], COPD patients
requiring mechanical ventilation without pneumonia were
randomly assigned to receive ofloxacin or placebo. Mortality
and other outcome measures were much worse in patients
receiving placebo. Most of these patients probably were
admitted with infectious bronchitis. In contrast, in an
observational study conducted some years ago, Fagon and
coworkers [7] could not find any difference in outcome in
patients suffering an exacerbation of COPD that required
mechanical ventilation whether they were treated with
antibiotics or not. In our opinion, PPMs in high counts in
patients with symptoms of infection must be treated with
antibiotics. We demonstrated some years ago [8] that in
stable COPD patients the presence of PPMs at low
concentrations (≥100 colony-forming units/ml) is associated
with a significant local inflammatory response. On the other
hand, it is not infrequent in clinical practice to observe
weaning failure in patients who have purulent secretions and
an endotracheal aspirate with growth of PPMs. Usually, when
these patients receive antibiotics for few days weaning failure
is reversed and they can be successfully extubated. What we
do not know is for how long we must treat these patients.
Probably, short courses of antibiotics should be sufficient.
In summary, VAT is a nosocomial infection with no validated
definition. Consequently, we do not know what proportion of
these patients have real ventilator-associated pneumonia.
Studies involving CT scans are needed to establish this. It
seems that VAT caused by PPMs at high concentrations is
associated with an increased period of mechanical ventilation
and length of stay. Our recommendation is to treat these
patients with antibiotics, particularly when they present with
persistent weaning failure.
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